SM Merger/Arbitrage, L.P. et al v. Bristol-Myers Squibb Company et al
Case Number:
1:21-cv-08255
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
March 01, 2024
NY Judge Tosses $6.4B BMS Investor Action For Good
Celgene Corp. investors could not convince a New York federal judge that Bristol-Myers Squibb Co. was intentionally trying to flout securities law by delaying the U.S. Food and Drug Administration's approval of a cancer treatment in order to avoid giving them a $6.4 billion payout.
-
March 01, 2023
Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now
A Manhattan federal judge Wednesday dismissed a proposed class action alleging Bristol-Myers Squibb Co. and its executives intentionally delayed the U.S. Food and Drug Administration's approval of a cancer treatment developed by subsidiary Celgene Corp. to avoid making a $6.4 billion payment to investors.